rabies vaccine (University of Oxford)

The rabies vaccine, in the context of the University of Oxford's malaria research, serves as an active control in clinical trials for *Plasmodium falciparum* vaccine candidates, such as the RH5-based vaccines (ChAd63-RH5 and MVA-RH5). In the Phase Ib trial (NCT03435874) conducted in Tanzania, this vaccine was administered to participants in the control group to maintain a double-blind study design. Using a licensed vaccine like the rabies vaccine as a control ensures that participants in the control arm receive a tangible health benefit while providing a comparative baseline for assessing the safety and immunogenicity of experimental malaria vaccines. The vaccine functions by inducing protective immunity, primarily through the production of neutralizing antibodies against the rabies virus, and is not intended to provide protection against malaria.

Other names

Rabies Vaccine